{
  "stats": {
    "totalUrls": 318,
    "sitemap": 17,
    "high-page-views-low-form-views": 4,
    "alt-text": 1,
    "cwv": 10,
    "meta-tags": 278,
    "broken-internal-links": 8,
    "broken-backlinks": 0
  },
  "sitemap": [
    "astrazeneca.com/country-sites/vietnam.html",
    "astrazeneca.com/sustainability/access-to-healthcare.html",
    "astrazeneca.com/sustainability/resources/policies-and-standards.html",
    "astrazeneca.com/country-sites/uruguay.html",
    "astrazeneca.com/sustainability/environmental-protection.html",
    "astrazeneca.com/sustainability/ethics-and-transparency.html",
    "astrazeneca.com/country-sites/austria.html",
    "astrazeneca.com/media-centre/articles/2023/transforming-cardiovascular-care-burden-heart-failure.html",
    "astrazeneca.com/our-company/our-locations/cambridge/Community-in-Cambridge.html",
    "astrazeneca.com/sustainability/access-to-healthcare/affordability-and-pricing.html",
    "astrazeneca.com/media-centre/articles/2024/strengthening-health-systems-through-the-partnership-for-health-system-sustainability-and-resilience.html",
    "astrazeneca.com/legal-notice-and-terms-of-use/ro.html",
    "astrazeneca.com/sustainability/ethics-and-transparency/ethical-business-culture.html",
    "astrazeneca.com/sustainability/environmental-protection/ambition-zero-carbon.html",
    "astrazeneca.com/sustainability/environmental-protection/natural-resources.html",
    "astrazeneca.com/az-suppliers.html",
    "astrazeneca.com/media-centre/articles/2024/protecting-restoring-nature-for-a-healthier-future.html"
  ],
  "high-page-views-low-form-views": [
    "astrazeneca.com/media-centre/press-releases.html",
    "astrazeneca.com/what-science-can-do/topics/technologies/every-breath-counts-local-efforts-impact-global-asthma-care.html",
    "astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics.html",
    "astrazeneca.com/r-d/transformative-science.html"
  ],
  "alt-text": [
    "astrazeneca.com/country-sites/israel.html"
  ],
  "cwv": [
    "astrazeneca.com/media-centre/press-releases/2025/baxdrostat-demonstrated-statistically-significant-clinically-meaningful-reduction-sbp-patients-hard-control-hypertension-baxhtn-phase-iii-trial.html",
    "astrazeneca.com/investor-relations/events.html",
    "astrazeneca.com/what-science-can-do.html",
    "astrazeneca.com/media-centre/articles.html",
    "astrazeneca.com/content/astraz/media-centre/press-releases.html",
    "astrazeneca.com/media-centre/press-releases.html",
    "astrazeneca.com/media-centre/medical-releases.html",
    "astrazeneca.com/what-science-can-do/topics/clinical-innovation/leading-cardiovascular-renal-metabolism-innovation.html",
    "astrazeneca.com/search_results.s.html",
    "astrazeneca.com/"
  ],
  "meta-tags": [
    "astrazeneca.com/media-centre/press-releases/2012/FORXIGA-dapagliflozin-now-approved-in-European-Union-for-treatment-of-type-2-diabetes-14112012.html",
    "astrazeneca.com/our-therapy-areas/biopharmaceuticals.html",
    "astrazeneca.com/legal-notice-and-terms-of-use.html",
    "astrazeneca.com/what-science-can-do/topics/disease-understanding/endothelin-1.html",
    "astrazeneca.com/what-science-can-do/topics/sustainability/creating-culture-sustainability-across-labs.html",
    "astrazeneca.com/media-centre.html",
    "astrazeneca.com/media-centre/articles/optimising-asthma-care-patients-planet.html",
    "astrazeneca.com/country-sites/thailand.html",
    "astrazeneca.com/media-centre/press-releases/2025/imfinzi-improved-efs-in-early-stage-gastric-cancer.html",
    "astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/renal.html",
    "astrazeneca.com/media-centre/press-releases/2024/tagrisso-improved-pfs-in-stage-iii-lung-cancer.html",
    "astrazeneca.com/media-centre/press-releases/2020/farxiga-approved-in-the-us-for-the-treatment-of-heart-failure-in-patients-with-heart-failure-with-reduced-ejection-fraction.html",
    "astrazeneca.com/media-centre/press-releases/2024/astrazeneca-announces-the-completion-of-the-clinical-programme-to-support-the-transition-of-breztri-to-next-generation-propellant-with-near-zero-global-warming-potential.html",
    "astrazeneca.com/media-centre/press-releases/2023/andexxa-phase-iv-trial-stopped-early-after-achieving-pre-specified-criteria-on-haemostatic-efficacy-versus-usual-care.html",
    "astrazeneca.com/investor-relations/astrazeneca-adr-programme.html",
    "astrazeneca.com/media-centre/press-releases/2025/datroway-approved-in-us-for-egfrm-lung-cancer.html",
    "astrazeneca.com/media-centre/press-releases/2021/serum-institute-of-india-obtains-emergency-use-authorisation-in-india-for-astrazenecas-covid-19-vaccine.html",
    "astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-farxiga-treatment-type-2-diabetes-patients-13012014.html",
    "astrazeneca.com/media-centre/press-releases/2024/tagrisso-plus-chemo-approved-in-us-for-lung-cancer.html",
    "astrazeneca.com/r-d/next-generation-therapeutics/fragment-antibody.html",
    "astrazeneca.com/media-centre/press-releases/2025/trixeo-aerosphere-approved-in-the-uk-as-first-inhaled-respiratory-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential.html",
    "astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-manufacture-adcs-in-singapore.html",
    "astrazeneca.com/media-centre/press-releases/2022/camizestrant-significantly-delayed-disease-progression-in-advanced-er-positive-breast-cancer.html",
    "astrazeneca.com/media-centre/press-releases/2024/fda-accepts-dato-dxd-bla-for-nonsquamous-nsclc.html",
    "astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-new-easy-to-use-once-weekly-bydureon-bcise-injectable-medicine-for-patients-with-type-2-diabetes-231017.html",
    "astrazeneca.com/media-centre/press-releases/2022/tagrisso-demonstrated-5-year-median-disease-free-survival-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.html",
    "astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-showcase-latest-research-on-comprehensive-portfolio-and-pipeline-aimed-at-transforming-respiratory-diseases-at-ats-2025.html",
    "astrazeneca.com/media-centre/press-releases/2025/new-study-results-reinforce-tagrisso-as-the-backbone-therapy-for-egfr-mutated-lung-cancer-across-stages-and-settings.html",
    "astrazeneca.com/media-centre/press-releases/2019/linzess-linaclotide-approved-in-china-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-18012019.html",
    "astrazeneca.com/r-d/our-technologies/functional-genomics.html",
    "astrazeneca.com/media-centre/press-releases/2023/update-on-pacific-2-phase-iii-trial-for-imfinzi.html",
    "astrazeneca.com/media-centre/press-releases/2025/update-on-anselamimab-in-al-amyloidosis.html",
    "astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-us-for-limited-stage-sclc.html",
    "astrazeneca.com/media-centre/press-releases/2023/zibotentan-dapagliflozin-combination-demonstrated-significant-albuminuria-reduction-in-patients-with-chronic-kidney-disease-and-proteinuria-in-zenith-ckd-phase-IIb-trial.html",
    "astrazeneca.com/media-centre/press-releases/2025/trixeo-aerosphere-receives-positive-eu-chmp-opinion-first-inhaled-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential.html",
    "astrazeneca.com/media-centre/press-releases/2025/enhertu-combination-improved-pfs-in-1l-her-positive-mbc.html",
    "astrazeneca.com/media-centre/press-releases/2017/fasenra-benralizumab-receives-us-fda-approval-for-severe-uncontrolled-eosinophilic-asthma-14112017.html",
    "astrazeneca.com/investor-relations.html",
    "astrazeneca.com/media-centre/press-releases/2025/camizestrant-improved-pfs-in-1l-hr-breast-cancer.html",
    "astrazeneca.com/media-centre/press-releases/2023.html",
    "astrazeneca.com/media-centre/press-releases/2021/two-billion-doses-of-astrazenecas-covid-19-vaccine-supplied-to-countries-across-the-world-less-than-12-months-after-first-approval.html",
    "astrazeneca.com/investor-relations/annual-reports/annual-report-2023.html",
    "astrazeneca.com/sustainability/climate-change/az-forest.html",
    "astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-to-acquire-Ardea-Biosciences-for-1-billion-23042012.html",
    "astrazeneca.com/media-centre/press-releases/2023/astrazeneca-agreement-with-quell-therapeutics.html",
    "astrazeneca.com/media-centre/press-releases/2019/astrazenecas-triple-combination-therapy-approved-in-china-for-patients-with-copd-23122019.html",
    "astrazeneca.com/media-centre/press-releases/2024/tagrisso-us-approval-in-unresectable-lung-cancer.html",
    "astrazeneca.com/media-centre/medical-releases/US-FDA-approves-Symbicort-budesonide-formoterol-for-the-treatment-of-asthma-in-paediatric-patients-300120170.html",
    "astrazeneca.com/az-suppliers/az-coupa-supplier/faq/coupa-supplier-portal.html",
    "astrazeneca.com/media-centre/press-releases/2022/camizestrant-significantly-improved-progression-free-survival.html",
    "astrazeneca.com/media-centre/press-releases/2025/calquence-combination-approved-in-us-for-1l-mcl.html",
    "astrazeneca.com/media-centre/press-releases/2025/enhertu-approved-in-us-for-breast-cancer-post-et.html",
    "astrazeneca.com/media-centre/press-releases/2024/tagrisso-the-addition-chemotherapy-showed-favourable-trend-overall-survival-egfr-mutated-advanced-lung-cancer-further-follow-flaura2-phase-iii-trial.html",
    "astrazeneca.com/media-centre/press-releases/2025/camizestrant-reduced-the-risk-of-disease-progression-or-death-by-56-in-patients-with-advanced-hr-positive-breast-cancer-with-an-emergent-esr1-tumour-mutation-in-serena-6-phase-iii-trial.html",
    "astrazeneca.com/media-centre/press-releases/2024/enhertu-improved-pfs-in-her2-low-and-ultralow.html",
    "astrazeneca.com/media-centre/press-releases/2024/supernova-trial-met-covid-19-prevention-endpoint.html",
    "astrazeneca.com/media-centre/press-releases/2023/agreement-with-eccogene-for-clinical-stage-glp-1ra.html",
    "astrazeneca.com/investor-relations/shareholder-information.html",
    "astrazeneca.com/media-centre/press-releases/2023/astrazeneca-enters-license-agreement-with-kym-biosciences-for-cmg901-a-claudin-182-antibody-drug-conjugate.html",
    "astrazeneca.com/media-centre/press-releases/2024/datopotamab-deruxtecan-final-overall-survival-results-reported-in-patients-with-metastatic-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-iii-trial.html",
    "astrazeneca.com/media-centre/press-releases/2024/positive-results-japan-phase-iii-trial-acoramidis-transthyretin-mediated-amyloid-cardiomyopathy-attr-cm-consistency-global-attribute-cm-phase-iii.html",
    "astrazeneca.com/media-centre/press-releases/2024/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-for-patients-with-limited-stage-small-cell-lung-cancer-in-the-us.html",
    "astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Pfizer-enter-agreement-for-over-the-counter-NEXIUM-AstraZeneca-raises-2012-guidance-13082012.html",
    "astrazeneca.com/media-centre/press-releases/2024/tagrisso-approved-in-eu-based-on-laura-trial.html",
    "astrazeneca.com/media-centre/press-releases/2025/enhertu-plus-pertuzumab-reduced-the-risk-of-disease-progression-or-death-vs-thp-as-1st-line-therapy-in-patients-with-her2-positive-metastatic-breast-cancer.html",
    "astrazeneca.com/country-sites/singapore.html",
    "astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html",
    "astrazeneca.com/investor-relations/annual-reports/annual-report-2024.html",
    "astrazeneca.com/r-d/next-generation-therapeutics/bispecific-antibody.html",
    "astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-us-for-resectable-lung-cancer.html",
    "astrazeneca.com/media-centre/press-releases/2025/baxdrostat-met-primary-and-all-secondary-endpts-in-baxhtn-phiii-trial.html",
    "astrazeneca.com/country-sites/african-cluster.html",
    "astrazeneca.com/media-centre/medical-releases/saphnelo-demonstrates-higher-rates-of-remission-in-patients-with-systemic-lupus-erythematosus-compared-to-standard-therapy-alone-over-4-year-period.html",
    "astrazeneca.com/media-centre/press-releases/2025/azd0780-a-novel-oral-pcsk9-inhibitor-demonstrated-significant-ldl-cholesterol-ldl-c-reduction-in-pursuit-phase-iib-trial.html",
    "astrazeneca.com/our-therapy-areas/oncology/dna-damage-response.html",
    "astrazeneca.com/media-centre/press-releases/2019/fasenra-approved-in-the-us-for-self-administration-in-a-new-pre-filled-auto-injector-the-fasenra-pen-04102019.html",
    "astrazeneca.com/media-centre/press-releases/2023/tezspire-approved-for-self-administration-in-the-us-with-a-new-pre-filled-pen.html",
    "astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/liquid-biopsy-ctdna.html",
    "astrazeneca.com/our-therapy-areas/respiratory-and-immunology.html",
    "astrazeneca.com/country-sites/the-philippines.html",
    "astrazeneca.com/country-sites/taiwan.html",
    "astrazeneca.com/media-centre/press-releases/2025/dato-dxd-approved-in-us-for-hr-p-breast-cancer.html",
    "astrazeneca.com/media-centre/press-releases/2023/beyfortus-approved-in-the-us-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants.html",
    "astrazeneca.com/media-centre/press-releases/2017/astrazeneca-enters-agreement-with-grunenthal-to-divest-rights-to-migraine-treatment-zomig-07062017.html",
    "astrazeneca.com/country-sites/ireland.html",
    "astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html",
    "astrazeneca.com/media-centre/press-releases/2023/astrazeneca-settles-nexium-and-prilosec-product-liability-litigations.html",
    "astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-the-us-for-bladder-cancer.html",
    "astrazeneca.com/country-sites/lithuania.html",
    "astrazeneca.com/media-centre/press-releases/2023/lynparza-approved-in-us-for-brcam-prostate-cancer.html",
    "astrazeneca.com/media-centre/press-releases/2024/ultomiris-approved-in-the-us-for-nmosd.html",
    "astrazeneca.com/content/dam/az/media-centre-docs/article_files/articles-2020/11229%20-%20AZ-USASEF-Moldy-Bread-v7-STEM-Day-Version-GY-FH.pdf",
    "astrazeneca.com/content/dam/azcovid/pdf/dominican-republic/es-PI-AZD1222.pdf",
    "astrazeneca.com/media-centre/press-releases/2019/new-data-show-symbicort-reduces-attacks-in-mild-asthma-when-used-as-an-anti-inflammatory-reliever-20052019.html",
    "astrazeneca.com/content/dam/az/Country-Sites/Country-sites-single-pagers/Taiwan/Medicines/023310-Pulmicort-Nasal-Aqua-64ug-2022321934-2001325991.pdf",
    "astrazeneca.com/our-company/contact-us.html",
    "astrazeneca.com/our-company/history.html",
    "astrazeneca.com/what-science-can-do/topics/disease-understanding/unpacking-raas-pathway-role-aldosterone.html",
    "astrazeneca.com/media-centre/press-releases/2020/breztri-aerosphere-approved-in-the-us-for-copd.html",
    "astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquires-cincor-for-cardiorenal-asset.html",
    "astrazeneca.com/content/dam/azcovid/pdf/vietnam/HCP-leaflet-SBS-VNese.pdf",
    "astrazeneca.com/our-therapy-areas/oncology/medicines-portfolio-and-pipeline.html",
    "astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-amolyt.html",
    "astrazeneca.com/investor-relations/dividend-policy.html",
    "astrazeneca.com/investor-relations/full-year-and-q4-2024-results-event.html",
    "astrazeneca.com/content/dam/az/Country-Sites/Greece/pdf/NOLVADEX_FC.TAB_10_20_PIL-091123.pdf",
    "astrazeneca.com/content/dam/az/az-supplier/pdf/%E3%82%88%E3%81%8F%E3%81%82%E3%82%8B%E8%B3%AA%E5%95%8F.pdf",
    "astrazeneca.com/what-science-can-do/topics/disease-understanding/Hitting-the-bullseye-finding-better-targets-for-drug-development.html",
    "astrazeneca.com/country-sites/serbia.html",
    "astrazeneca.com/media-centre/press-releases/2025/enhertu-approved-in-eu-in-post-et-breast-cancer.html",
    "astrazeneca.com/media-centre/press-releases/2013/astrazeneca-pearl-therapeutics-respiratory-disease-10062013.html",
    "astrazeneca.com/global/en/AstraZeneca-Websites.html",
    "astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-the-us-for-eosinophilic-granulomatosis-with-polyangiitis.html",
    "astrazeneca.com/media-centre/press-releases/2011/fda-approves-new-medicine-brilinta--ticagrelor--for-use-in-the-us-20072011.html",
    "astrazeneca.com/our-therapy-areas.html",
    "astrazeneca.com/our-therapy-areas/oncology/leading-the-revolution-in-pancreatic-cancer.html",
    "astrazeneca.com/media-centre/press-releases/2023/tagrisso-demonstrated-strong-overall-survival-benefit-in-the-adaura-phase-iii-trial.html",
    "astrazeneca.com/r-d/data-science-and-ai.html",
    "astrazeneca.com/media-centre/press-releases/2022/astrazeneca-to-acquire-neogene-therapeutics-accelerating-ambition-in-oncology-cell-therapy.html",
    "astrazeneca.com/content/dam/az/Country-Sites/Country-sites-single-pagers/Taiwan/Medicines/Betaloc-ZOK-100mg.pdf",
    "astrazeneca.com/media-centre/press-releases.html",
    "astrazeneca.com/country-sites/thailand/press-releases/covid-19-vaccine-provides-equally-effective-protection-against-hospitalisation-and-deaths-compared-with-mrna-vaccines-th.html",
    "astrazeneca.com/media-centre/press-releases/2014/us-fda-approved-xigduo-type-2-diabetes-patients-30102014.html",
    "astrazeneca.com/content/dam/azcovid/pdf/hungary/hu-epil-AZD1222.pdf",
    "astrazeneca.com/media-centre/press-releases/2024/acquisition-of-amolyt-pharma-completed.html",
    "astrazeneca.com/investor-relations/results-and-presentations.html",
    "astrazeneca.com/bin/downloadlink",
    "astrazeneca.com/r-d/next-generation-therapeutics/small-molecule.html",
    "astrazeneca.com/media-centre/press-releases/2021/tezspire-tezepelumab-approved-in-the-us-for-severe-asthma.html",
    "astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/hMPV.html",
    "astrazeneca.com/content/dam/az/PDF/2020/covid-19-toolkit/Managing_Conflicting_Priorities.pdf",
    "astrazeneca.com/media-centre/press-releases/2024/lynparza-demonstrated-clinically-meaningful-prolonged-survival-benefit-in-early-breast-cancer-in-olympia-phase-iii-trial.html",
    "astrazeneca.com/media-centre/press-releases/2009/US-FDA-Approves-Seroquel-XR-For-AddOn-Treatment-Of-Major-Depressive-Disorder-04122009.html",
    "astrazeneca.com/media-centre/press-releases/2024/acquisition-of-fusion-completed.html",
    "astrazeneca.com/country-sites/egypt.html",
    "astrazeneca.com/media-centre/press-releases/2024/Enhertu-demonstrated-median-progression-free-survival-thirteen-months.html",
    "astrazeneca.com/our-company/leadership.html",
    "astrazeneca.com/media-centre/press-releases/2021/farxiga-approved-in-the-us-for-ckd.html",
    "astrazeneca.com/media-centre/press-releases/2024/flumist-approved-for-self-administration-in-the-us.html",
    "astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-advanced-liver-cancer.html",
    "astrazeneca.com/r-d/next-generation-therapeutics/sodium-zirconium-cyclosilicate.html",
    "astrazeneca.com/our-company/our-locations/gaithersburg.html",
    "astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/developing-the-next-generation-of-drug-delivery-technologies.html",
    "astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html",
    "astrazeneca.com/country-sites/israel.html",
    "astrazeneca.com/content/dam/az/Country-Sites/Country-sites-single-pagers/Taiwan/Medicines/BRICANYL-TURBUHALER-05M.pdf",
    "astrazeneca.com/our-company/our-people/anas-younes.html",
    "astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquire-cincor-for-cardiorenal-asset.html",
    "astrazeneca.com/media-centre/articles/2022/celebrating-the-life-and-legacy-of-jose-baselga.html",
    "astrazeneca.com/country-sites/gulf.html",
    "astrazeneca.com/our-company/leadership/susan-galbraith.html",
    "astrazeneca.com/content/dam/az/Country-Sites/Country-sites-single-pagers/Taiwan/Medicines/023799-Betaloc-ZOK-25mg20013259912022321934---201207202668020934.pdf",
    "astrazeneca.com/media-centre/press-releases/2024/dato-dxd-showed-median-overall-survival-of-146-months-in-patients-with-advanced-nsclc-in-tropion-lung01-phase-iii-trial.html",
    "astrazeneca.com/media-centre/press-releases/2024/astrazeneca-completes-acquisition-of-icosavax.html",
    "astrazeneca.com/content/dam/az-ca/downloads/productinformation/zomig-zomig-rapimelt-consumer-information-leaflet-en.pdf",
    "astrazeneca.com/content/dam/azcovid/pdf/covax/who-clean-pl-azd1222-pt.pdf",
    "astrazeneca.com/our-company/our-locations/cambridge.html",
    "astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-fusion.html",
    "astrazeneca.com/our-therapy-areas/pipeline.html",
    "astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/t-cell-receptor-therapies.html",
    "astrazeneca.com/media-centre/press-releases/2023/airsupra-pt027-approved-in-the-us-for-asthma.html",
    "astrazeneca.com/content/dam/az/Country-Sites/Country-sites-single-pagers/Taiwan/Medicines/Zestril-Tab-51020mg.pdf",
    "astrazeneca.com/media-centre/press-releases/2015/iressa-fda-approved-non-small-cell-lung-cancer-treatment-13072015.html",
    "astrazeneca.com/content/dam/az/Country-Sites/Country-sites-single-pagers/Taiwan/Medicines/CRESTOR-FC-Tab-5mg-10mg-20mg.pdf",
    "astrazeneca.com/investor-relations/stock-exchange-announcements.html",
    "astrazeneca.com/investor-relations/9m-and-q3-2024-results-event.html",
    "astrazeneca.com/media-centre/image-and-broadcast-library.html",
    "astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/the-dawn-of-a-new-era-in-chronic-kidney-disease.html",
    "astrazeneca.com/r-d/next-generation-therapeutics/antibody-drug-conjugate.html",
    "astrazeneca.com/content/dam/az-ch/pdf/2023/dec/2023-12-price-list-AZ-DE.pdf",
    "astrazeneca.com/content/dam/az-ca/downloads/productinformation/byetta-consumer-information-leaflet-en.pdf",
    "astrazeneca.com/media-centre/press-releases/2024/farxiga-approved-in-the-us-for-the-treatment-of-paediatric-type-2-diabetes.html",
    "astrazeneca.com/our-therapy-areas/respiratory-and-immunology/lupus.html",
    "astrazeneca.com/media-centre/press-releases/2025/update-on-capitello-280-phase-iii-trial.html",
    "astrazeneca.com/our-company/our-people/bob-li.html",
    "astrazeneca.com/investor-relations/annual-reports.html",
    "astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-icosavax-including-potential-first-in-class-rsv-and-hmpv-combination-vaccine-with-positive-phase-ii-data.html",
    "astrazeneca.com/media-centre/press-releases/2022/astrazeneca-announces-plans-for-new-strategic-rd-centre-and-alexion-headquarters-in-cambridge-massachusetts.html",
    "astrazeneca.com/our-therapy-areas/oncology.html",
    "astrazeneca.com/media-centre/press-releases/2023/acquisition-of-neogene-therapeutics-completed.html",
    "astrazeneca.com/country-sites/croatia.html",
    "astrazeneca.com/media-centre/press-releases/2023/xigduo-xr-approved-in-china-for-adults-with-type-2-diabetes.html",
    "astrazeneca.com/country-sites/indonesia.html",
    "astrazeneca.com/content/dam/az/PDF/2020/covid-19-toolkit/Burnout_Self-Test.pdf",
    "astrazeneca.com/country-sites/thailand/press-releases/common-seasonal-diseases-in-children-TH.html",
    "astrazeneca.com/media-centre/press-releases/2025/breztri-met-primary-endpoints-in-ph3-asthma-trials.html",
    "astrazeneca.com/content/dam/az/media-centre-docs/article_files/articles-2020/11229%20-%20AZ-USASEF-Agar-Experiment-v7-STEM-Day-Version-GY-FH.pdf",
    "astrazeneca.com/content/dam/az/our-company/our-company-052017/investor-relations/presentations-and-webcast/2014/Presenter-biographies.pdf",
    "astrazeneca.com/our-company.html",
    "astrazeneca.com/media-centre/press-releases/2022/ultomiris-approved-in-the-us-for-adults-with-generalised-myasthenia-gravis.html",
    "astrazeneca.com/media-centre/press-releases/2023/tagrisso-achieved-unprecedented-survival-in-early-stage-egfr-mutated-lung-cancer-with-88-of-patients-alive-at-five-years-in-adaura-phase-iii-trial.html",
    "astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html",
    "astrazeneca.com/content/dam/az/PDF/2020/covid-19-toolkit/Building_Great_Work_Relationships.pdf",
    "astrazeneca.com/sustainability/access-to-healthcare/healthy-heart-africa.html",
    "astrazeneca.com/r-d/next-generation-therapeutics/gene-therapy.html",
    "astrazeneca.com/content/dam/az/Country-Sites/Country-sites-single-pagers/Taiwan/Medicines/Seroquel-Tablets-25mg-100mg-300mg.pdf",
    "astrazeneca.com/our-therapy-areas/oncology/immuno-oncology.html",
    "astrazeneca.com/investor-relations/faqs.html",
    "astrazeneca.com/content/dam/az/Country-Sites/Greece/pdf/LOKELMA-PIL-approved-26-APR-2023.pdf",
    "astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/covid-19.html",
    "astrazeneca.com/content/dam/az/our-company/Sustainability/Business-Travel-Policy-v5-0.pdf",
    "astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-the-us-for-sle.html",
    "astrazeneca.com/media-centre/press-releases/2025/tagrisso-plus-chemotherapy-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-in-egfr-mutated-advanced-lung-cancer.html",
    "astrazeneca.com/our-therapy-areas/oncology/at-the-forefront-of-lung-cancer-treatment.html",
    "astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/unique-complexities-cell-therapy-manufacturing.html",
    "astrazeneca.com/r-d/next-generation-therapeutics/protacs.html",
    "astrazeneca.com/r-d/precision-medicine.html",
    "astrazeneca.com/content/dam/az/Country-Sites/Country-sites-single-pagers/Taiwan/Medicines/Nexium-Tab-20mg-40mg.pdf",
    "astrazeneca.com/media-centre/press-releases/2024/enhertu-approved-in-the-us-as-first-tumour-agnostic-her2-directed-therapy-for-previously-treated-patients-with-metastatic-her2-positive-solid-tumours.html",
    "astrazeneca.com/content/young-health.html",
    "astrazeneca.com/our-therapy-areas/rare-disease.html",
    "astrazeneca.com/media-centre/press-releases/2014/fda-approved-movatnik-opioid-induced-constipation-chronic-non-cancer-pain-patients-16092014.html",
    "astrazeneca.com/media-centre/pdf.html",
    "astrazeneca.com/content/dam/az/Country-Sites/Country-sites-single-pagers/Taiwan/Medicines/EMLA-Cream-5.pdf",
    "astrazeneca.com/content/dam/azcovid/pdf/germany/de-epil-AZD1222.pdf",
    "astrazeneca.com/country-sites/greece.html",
    "astrazeneca.com/our-company/our-people/tom-keith-roach.html",
    "astrazeneca.com/our-company/our-people/matt-hellmann.html",
    "astrazeneca.com/media-centre/press-releases/2023/wainua-eplontersen-granted-first-ever-regulatory-approval-us-treatment-of-adults-with-polyneuropathy-hereditary-transthyretin-mediated-amyloidosis.html",
    "astrazeneca.com/media-centre/press-releases/2023/farxiga-extended-in-the-us-for-heart-failure.html",
    "astrazeneca.com/content/dam/azcovid/pdf/dominican-republic/es-PIL-AZD1222.pdf",
    "astrazeneca.com/media-centre/press-releases/2020/trixeo-aerosphere-approved-in-the-eu-for-copd.html",
    "astrazeneca.com/media-centre/press-releases/2025/eneboparatide-phase-iii-trial-met-primary-endpoint.html",
    "astrazeneca.com/content/dam/az/Country-Sites/Country-sites-single-pagers/Taiwan/Medicines/Imdur-CR-Tab60mg.pdf",
    "astrazeneca.com/r-d/next-generation-therapeutics/cell-therapies.html",
    "astrazeneca.com/content/dam/azcovid/pdf/malaysia/en-PIL-AZD1222.pdf",
    "astrazeneca.com/content/dam/az/Country-Sites/Country-sites-single-pagers/Taiwan/Medicines/Seroquel-Tablets-200mg.pdf",
    "astrazeneca.com/media-centre/press-releases/2018/lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hyperkalaemia-21052018.html",
    "astrazeneca.com/media-centre/press-releases/2021/orpathys-approved-in-china-for-patients-with-lung-cancer-and-met-gene-alterations.html",
    "astrazeneca.com/media-centre/press-releases/2023/truqap-approved-in-us-for-hr-plus-breast-cancer.html",
    "astrazeneca.com/media-centre/press-releases/2025/gefurulimab-nanobody-met-phase-iii-endpoints.html",
    "astrazeneca.com/our-therapy-areas/oncology/breast-cancer.html",
    "astrazeneca.com/media-centre/press-releases/2024/datopotamab-deruxtecan-granted-breakthrough-therapy-designation-us-patients-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer.html",
    "astrazeneca.com/content/dam/azcovid/pdf/brunei/en-PIL-AZD1222.pdf",
    "astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies.html",
    "astrazeneca.com/media-centre/press-releases/2021/statement-on-the-passing-of-jose-baselga.html",
    "astrazeneca.com/our-therapy-areas/medicines.html",
    "astrazeneca.com/media-centre/press-releases/2024/update-on-capitello-290-phase-iii-trial.html",
    "astrazeneca.com/",
    "astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-china-for-the-treatment-of-severe-eosinophilic-asthma.html",
    "astrazeneca.com/country-sites/thailand/press-releases/th-astrazeneca-completes-delivery-of-61-million-covid-19-vaccine-doses-to-thailand.html",
    "astrazeneca.com/investor-relations/h1-and-q2-2025-results-event.html",
    "astrazeneca.com/investor-relations/h1-and-q2-2024-results-event.html",
    "astrazeneca.com/r-d/our-strategic-r-d-centres.html",
    "astrazeneca.com/media-centre/press-releases/2019/update-on-us-regulatory-decision-for-farxiga-in-type-1-diabetes-15072019.html",
    "astrazeneca.com/investor-relations/q1-2024-results-event.html",
    "astrazeneca.com/what-science-can-do/topics/clinical-innovation/data-visualisation-turning-science-into-stories.html",
    "astrazeneca.com/sustainability/health-equity/healthy-heart-africa.html",
    "astrazeneca.com/r-d/next-generation-therapeutics/T-cell-engager.html",
    "astrazeneca.com/r-d/next-generation-therapeutics/multispecifics.html",
    "astrazeneca.com/media-centre/articles/2023/detecting-amyloidosis-understanding-the-different-types-of-attr.html",
    "astrazeneca.com/media-centre/press-releases/2025/enhertu-improved-pcr-in-early-stage-breast-cancer.html",
    "astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-acquire-alexion.html",
    "astrazeneca.com/content/dam/az-ca/downloads/productinformation/duaklir-consumer-information-leaflet-en.pdf",
    "astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-to-manufacture-adcs-in-singapore.html",
    "astrazeneca.com/investor-relations/annual-reports/annual-report-2022.html",
    "astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html",
    "astrazeneca.com/media-centre/press-releases/2025/tagrisso-plus-chemotherapy-demonstrated-a-median-overall-survival-of-nearly-four-years.html",
    "astrazeneca.com/media-centre/press-releases/2022/astrazeneca-announces-sale-of-west-chester-site.html",
    "astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-to-hire-over-800-employees-to-produce-cancer-medicines-at-adc-manufacturing-facility-in-singapore.html",
    "astrazeneca.com/media-centre/press-releases/2025/baxdrostat-demonstrated-statistically-significant-clinically-meaningful-reduction-sbp-patients-hard-control-hypertension-baxhtn-phase-iii-trial.html",
    "astrazeneca.com/investor-relations/annual-reports/annual-report-2016/contact-information.html",
    "astrazeneca.com/media-centre/press-releases/2025/update-on-resolute-phase-iii-trial.html",
    "astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-takeda-establish-collaboration-to-develop-and-commercialise-medi1341-for-parkinsons-disease-25082017.html",
    "astrazeneca.com/content/dam/az/Country-Sites/Country-sites-single-pagers/Taiwan/Medicines/Plendil-ER-Tab-25mg-5mg-10mg.pdf",
    "astrazeneca.com/content/dam/az/Country-Sites/Greece/pdf/SEROQUEL_FC.TAB_25_100_200_300_SPC-010222.pdf",
    "astrazeneca.com/content/dam/az/Country-Sites/Greece/pdf/CRESTOR-FC-TAB-PIL-120523.pdf",
    "astrazeneca.com/content/dam/az/Country-Sites/Greece/pdf/SYMBICORT%20TURBUHALER_INH.PD_(160+4,5)_SPC-270921.pdf",
    "astrazeneca.com/our-company/our-people/sunil-verma.html",
    "astrazeneca.com/content/dam/azcovid/pdf/sweden/se-epil-AZD1222.pdf",
    "astrazeneca.com/content/dam/az/Country-Sites/Country-sites-single-pagers/Taiwan/Medicines/Onglyza-FC-Tab-25mg-5mg.pdf",
    "astrazeneca.com/content/dam/azcovid/pdf/romania/ro-esmpc-AZD1222.pdf",
    "astrazeneca.com/content/dam/az/PDF/2024/fy/Full-year-and-Q4-2024-results-announcement.pdf",
    "astrazeneca.com/content/dam/az/Country-Sites/Greece/pdf/SYMBICORT%20_INH.SUS.P_%20(pMDI)%20(160+4.5)_SPC-270921.pdf",
    "astrazeneca.com/media-centre/press-releases/2021/astrazeneca-unveils-the-discovery-centre-disc-in-cambridge.html",
    "astrazeneca.com/az-suppliers/az-coupa-supplier.html",
    "astrazeneca.com/investor-relations/contacts-information.html",
    "astrazeneca.com/what-science-can-do/topics/disease-understanding/strategic-treatment-combinations-cancer.html"
  ],
  "broken-internal-links": [
    "astrazeneca.com/our-therapy-areas/oncology/at-the-forefront-of-lung-cancer-treatment.html",
    "astrazeneca.com/our-therapy-areas/oncology/breast-cancer.html",
    "astrazeneca.com/r-d.html",
    "astrazeneca.com/what-science-can-do/topics/covid-19/immunobridging-trials.html",
    "astrazeneca.com/sustainability/nature/waste-circularity.html",
    "astrazeneca.com/content/astraz/our-therapy-areas/cardiovascular-renal-and-metabolism/cardiovascular-disease.html",
    "astrazeneca.com/media-centre/articles/2024/earlier-amyloidosis-diagnosis.html",
    "astrazeneca.com/media-centre/articles/2023/detecting-amyloidosis-understanding-the-different-types-of-attr.html"
  ],
  "broken-backlinks": []
}